Effects of Flavivirus Cross-Reactivity (Zika and Dengue) on the Development of Vaccines for Use in Pregnancy
Purpose of Review
The aim of this article is to discuss the implications of immunological cross-reactivity with other prevalent flaviviruses, such as DENV, for the development of a safe and effective vaccine against ZIKV.
The severe clinical manifestations of ZIKV can be due to antibody-dependent enhancement (ADE). This indicates that immunity against DENV and other flaviviruses influences ZIKV disease pathogenesis and the development of vaccines against ZIKV and DENV.
Zika is a re-emerging disease caused by the ZIKV with an unusual clinical presentation characterized by severe manifestations such as Guillain-Barré syndrome. In pregnancy, it can lead to abortion or congenital Zika syndrome (CZS). Currently, no specific treatment or licensed vaccine for this virus is available; therefore, there is an urgent need for the development of a vaccine that can be used during pregnancy.
Studies of vaccines against ZIKV are progressing positively, and in their designs, modifications of the antigens are being considered so that they do not cause cross reactions with other flaviviruses that can cause complications in people previously exposed to other flaviviruses
KeywordsFlavivirus Cross-reactivity Dengue Zika Vaccines Pregnancy
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.•• Dowd KA, Demaso CR, Pelc RS, Speer SD, Alexander R, Smith Y, et al. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Rep. 2016;16(6):1485–91. In this article, the authors present in a very clear and precise way the importance of developing robust neutralizing antibodies capable of inhibiting infection by both ZIKV lineages.CrossRefGoogle Scholar
- 3.Makhluf H, Shresta S. Development of Zika virus vaccines. Vaccines (Basel). 2018:1–9.Google Scholar
- 5.Moore CA, Staples JE, Dobyns WB, Pessoa A, Ventura CV, da Fonseca EB, et al. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. JAMA Pediatr [Internet]. 2017;171(3):288–95. Available from. https://doi.org/10.1001/jamapediatrics.2016.3982.CrossRefGoogle Scholar
- 6.Rice ME, Galang RR, Roth NM, Ellington SR, Moore CA, Valencia-Prado M, et al. Vital signs: Zika-associated birth defects and neurodevelopmental abnormalities possibly associated with congenital Zika virus infection — U.S. territories and freely associated states, 2018. MMWR Morb Mortal Wkly Rep [Internet]. 2018;67(31) Available from: http://www.cdc.gov/mmwr/volumes/67/wr/mm6731e1.htm?s_cid=mm6731e1_w.
- 8.Fritzell C, Rousset D, Adde A, Kazanji M, Van MD, Flamand C. Current challenges and implications for dengue , chikungunya and Zika seroprevalence studies worldwide : A scoping review. 2018;1–29.Google Scholar
- 10.• Priyamvada L, Hudson W, Ahmed R, Wrammert J. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. 2017;(April):1–6. This article discusses the importance of cross-humoral reactivity between DENV and ZIKV, reviewing the evidence and discussing the potential impact of this cross-recognition on the functional quality of antibody responses against ZIKV. Google Scholar
- 11.Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis [Internet]. 2009 Nov;9(11):678–87 Available from: http://linkinghub.elsevier.com/retrieve/pii/S1473309909702543.CrossRefGoogle Scholar
- 12.Who. Dengue and severe dengue [Internet]. WHO Fact Sheet. 2012. p. 1–4. Available from: www.who.int/mediacentre/factsheets/fs117/en/index.html
- 13.Swaminathan S, Khanna N. Dengue: recent advances in biology and current status of translational research. Curr Mol Med [Internet]. 2009;9(2):152–73 Available from: http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1566-5240&volume=9&issue=2&spage=152.CrossRefGoogle Scholar
- 16.Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol [Internet]. 2016;17:1102. Available from:. https://doi.org/10.1038/ni.3515.CrossRefGoogle Scholar
- 17.Didier H, Lucien P, Bertrand R, Philippe G, Eliane C, Gerard G, et al. Pecarere Jean-Louis VPRW and M. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg March. 1993;48:324–31.Google Scholar
- 18.Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-spaeth G, Duangchinda T, et al. Europe PMC Funders Group Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. 2017;17(9):1102–8.Google Scholar
- 19.Kularatne SAM. Dengue fever. 2015;4661(September):1–10.Google Scholar
- 20.Skipetrova A, Wartel TA, Gailhardou S. Dengue vaccination during pregnancy – an overview of clinical trials data. Vaccine [Internet]. 2018 May;36(23):3345–50 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X18305474.
- 21.•• Krubiner CB, Faden RR, Karron RA, Little MO, Lyerly AD, Abramson JS, et al. Pregnant women & vaccines against emerging epidemic threats: ethics guidance for preparedness , research , and response. Vaccine [Internet]. 2019;(xxxx). Available from: https://doi.org/10.1016/j.vaccine.2019.01.011. This article calls for the need to contemplate pregnant women in clinical studies of vaccines.
- 24.Brasil P, Pereira JP Jr, Raja Gabaglia C, Damasceno L, Wakimoto M, Ribeiro Nogueira RM, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med. 2016.Google Scholar
- 25.Simon C, Marianne B, Priscillia B, Timothée D, Prisca G-A, Dominique E-G, et al. Association between Zika virus and microcephaly in French Polynesia, 2013–15: a retrospective study. Lancet. 2016.Google Scholar
- 30.Faden RR, Krubiner CB, Lyerly AD, Little MO, August A, Beigi RH, et al. Ethics , pregnancy , and ZIKV vaccine research & development The Ethics Working Group on ZIKV Research and Pregnancy. Vaccine [Internet]. 2017;35(49):6819–22. Available from. https://doi.org/10.1016/j.vaccine.2017.09.065.CrossRefGoogle Scholar
- 32.WHO. Zika vaccine development technology roadmap [Internet]. 2019. Available from: https://www.who.int/immunization/research/development/Zika_Vaccine_Development_Technology_Roadmap_after_consultation_April_2019.pdf?ua=1
- 33.Omer SB, Beigi RH. Pregnancy in the time of Zika addressing barriers for developing vaccines and other measures for pregnant women. 2019;315(12).Google Scholar
- 36.Long F, Doyle M, Fernandez E, Miller AS, Klose T, Sevvana M, et al. Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope. Proc Natl Acad Sci U S A [Internet]. 2019 [cited 2019 Jul 3];116(5):1591–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30642974 CrossRefGoogle Scholar
- 37.Barrett ADT. Developing Zika vaccines: the lessons for disease X. 2018;4–6.Google Scholar
- 39.Castaño-Osorio J, María Giraldo-Garcia A, Isabel Giraldo M. Current status of vaccines against Dengue virus. In: Dengue fever - a resilient threat in the face of innovation [Internet]. IntechOpen; 2019. Available from: https://www.intechopen.com/books/dengue-fever-a-resilient-threat-in-the-face-of-innovation/current-status-of-vaccines-against-dengue-virus
- 40.Christofferson RC. Review article Zika virus emergence and expansion: lessons learned from dengue and chikungunya may not provide all the answers. 2016;95(1):15–8.Google Scholar
- 42.Zhao H, Fernandez E, Dowd KA, Pierson TC, Diamond MS, Fremont DH. Structural basis of Zika virus-specific antibody article structural basis of Zika virus-specific antibody protection. Cell [Internet]. 2016;166(4):1016–27. Available from:. https://doi.org/10.1016/j.cell.2016.07.020.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.García-Sastre A, Lim JK, Bardina SV, Brown JA, Foster GA, Krysztof D, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science (80- ). 2017.Google Scholar
- 46.Keasey SL, Pugh CL, Jensen SMR, Smith JL, Hontz RD, Durbin AP, et al. Antibody responses to Zika virus infections in environments of flavivirus endemicity. Clin Vaccine Immunol [Internet]. 2017;24(4). Available from: http://www.ncbi.nlm.nih.gov/pubmed/28228395%0A, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5382833
- 47.Mcarthur MA. Zika virus: recent advances towards the development of vaccines and therapeutics. 2017;Google Scholar
- 48.P. A, R.A. L, R.A. DLB, C.A. B, E.T. M, M. B, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science (80- ) [Internet]. 2016;353(6304):1129–32 Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L611675150%0Ahttp://dx.doi.org/10.1126/science.aah6157.CrossRefGoogle Scholar